Scopus: 3 citas, Google Scholar: citas,
Alzheimer's disease in Down syndrome : An overlooked population for prevention trials
Strydom, André (South London and Maudsley NHS Foundation Trust)
Coppus, Antonia (Department of Primary and Community Care, Radboud University Medical Center, Nijmegen)
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau)
Danek, Adrian (Department of Neurology, Ludwig-Maximilians-Universität München)
Fortea, Juan (Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down)
Hardy, John (Reta Lila Weston Institute, Institute of Neurology, University College London)
Levin, Johannes (German Center for Neurodegenerative Diseases (DZNE) site Munich)
Nuebling, Georg (Department of Neurology, Ludwig-Maximilians-Universität München)
Rebillat, Anne-Sophie (Institut Jérôme Lejeune)
Ritchie, Craig (Centre for Clinical Brain Sciences. University of Edinburgh)
van Duijn, Cornelia (Department of Epidemiology, Erasmus Medical Centre, Rotterdam)
Zaman, Shahid (Cambridgeshire & Peterborough NHS Foundation Trust (CBFT), Fulbourn Hospital)
Zetterberg, Henrik (Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital)
Universitat Autònoma de Barcelona

Fecha: 2018
Resumen: The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Individuals with DS have a lifetime risk for dementia in excess of 90%, and DS is now acknowledged to be a genetic form of AD similar to rare autosomal-dominant causes. Just as DS put the spotlight on amyloid precursor protein mutations, it is also likely to inform us of the impact of manipulating the amyloid pathway on treatment outcomes in AD. Ironically, however, individuals with DS are usually excluded from AD trials. This review will discuss primary and secondary prevention trials for AD in DS and the potential barriers and solutions to such trials and describe the Europe-wide Horizon21 Consortium to establish a DS-AD prevention clinical trials network.
Nota: Número d'acord de subvenció WT/098330-Z-12-Z
Derechos: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. Creative Commons
Lengua: Anglès.
Documento: article ; recerca ; publishedVersion
Materia: Alzheimer's disease ; Down syndrome ; Trisomy 21 ; Randomized controlled trials ; Prevention ; Dementia ; APP ; Amyloid ; Biomarkers
Publicado en: Alzheimer's & Dementia : Translational Research & Clinical Interventions, Vol. 4 (december 2018) , p. 703-713, ISSN 2352-8737

PMID: 30581976
DOI: 10.1016/j.trci.2018.10.006

11 p, 1.2 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació Biomèdica Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados

 Registro creado el 2019-05-06, última modificación el 2019-07-17

   Favorit i Compartir